What Happened? Shares of scientific consulting firm Exponent (NASDAQ:EXPO) jumped in the afternoon session after UBS raised ...

Fintel reports that on December 15, 2025, UBS maintained coverage of Exponent (NasdaqGS:EXPO) with a Neutral recommendation.

If you are wondering whether Exponent is a bargain or a trap at today’s price, you are not alone. This breakdown is designed to help you see what the market might be missing. The stock has slipped 1.6 ...

There's no foolproof way to know the future for Exponent (NAS: EXPO) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock ...

Earnings from consulting firm Exponent (NASDAQ: EXPO) came in below expectations, and the company continues to see challenges heading into 2024. Investors are moving to the sidelines, sending shares ...

Baron Funds, an investment management company, released its “Baron Small Cap Fund” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. A general sense of optimism was ...

Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...